NovoRapid contains Short-acting insulin Aspart Aspart is genetically modified insulin analogues and has full biologic activity but less tendency for self-aggregation, resulting in more rapid absorption and onset of action and a shorter duration of action. These characteristics are particularly advantageous for allowing entrainment of insulin injection and action to rising plasma glucose levels following meals. The shorter duration of action also appears to be associated with a decreased number of hypoglycemic episodes, primarily because the decay of insulin action corresponds to the decline in plasma glucose after a meal. Thus, insulin aspart (novorapid) is preferred over regular insulin (Human Actrapid) for prandial coverage.